₹1,345.20 18.90 (1.43%)
As on October 12, 2026
Alivus Life Sciences Limited, a Mumbai, India-headquartered entity established in 2001, operates as a subsidiary of Nirma Limited. Having rebranded from Glenmark Life Sciences Limited in December 2024, the company specializes in the development, production, and global commercialization of active pharmaceutical ingredients (APIs). Its market footprint spans India, Japan, Europe, and both North and Latin America, supported by substantial export operations. Alivus Life Sciences provides an extensive catalog of APIs, including olmesartan, telmisartan, solifenacin, sitagliptin, zonisamide, rosuvastatin, amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, atovaquone, etoricoxib, remogliflozin, cabozantinib, and palbociclib. These ingredients are utilized across a diverse array of therapeutic areas, such as cardiovascular diseases, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, immunosuppression, respiratory and ophthalmological conditions, urology, and anti-infectives. Additionally, the company extends its expertise by offering contract development and manufacturing services (CDMO) to numerous multinational corporations and specialty pharmaceutical enterprises.
Total Revenue (YTD)
₹25.5KCAGR 5-Year
+4.70%Sun Pharmaceutical Industries Ltd
Market cap: ₹4,41,477.63 Cr
Divi's Laboratories Ltd
Market cap: ₹2,41,576.41 Cr
Torrent Pharmaceuticals Ltd
Market cap: ₹1,82,576.57 Cr
Missed the last rally? Don’t miss the next
Our AI-powered Analytical Portal finds the strongest technical positive stocks with actionable Buy & Sell opportunities.